# US 2024/0002956 A1 · SENSITIVE QUANTITATIVE DETECTION OF SARS-CoV-2 USING DIGITAL WARM-START CRISPR ASSAY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002956 A1
- Document ID: US20240002956A1
- Status: Published application
- Kind: A1
- Application number: 18/037,361
- Filed: 2021-11-17
- Published: 2024-01-04
- Earliest claimed: 2020-11-18
- Applicants: University of Connecticut
- Inventors: XIONG DING; CHANGCHUN LIU
- Web page: https://patentgrep.com/patent/US20240002956A1

## CPC

- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6851: Quantitative amplification
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure provides materials and methods for detection of pathogens. In particular, the disclosure provides primers and compositions for detection of viral pathogens, such as SARS-CoV-2. In addition, the disclosure provides a warm-start digital CRISPR assay for detection of viral pathogens, including SARS-CoV-2.

## Claims

### Claim 1

A digital warm-start assay for detecting a target in a sample, assay comprising:
a. contacting a sample with a warm-start CRISPR reaction mixture, the warm-start CRISPR reaction mixture comprising a Cas endonuclease, a target-specific crRNA, outer primers for amplification of the target, phosphorothioated inner primers for amplification of the target, and pyrophosphatase;
b. partitioning the warm-start CRISPR reaction mixture into a plurality of microwells;
c. amplifying the target, if present in the sample, by isothermal amplification; and
d. detecting a signal in each of the plurality of microwells, wherein detection of the signal in a given microwell indicates the presence of the target in the microwell.

### Claim 2

A digital warm-start assay for detecting a target in a sample, assay comprising:
a. providing a warm-start CRISPR reaction mixture, the warm-start CRISPR reaction mixture comprising a Cas endonuclease, a target-specific crRNA, outer primers for isothermal amplification of the target, phosphorothioated inner primers for isothermal amplification of the target, and pyrophosphatase;
b. partitioning the warm-start CRISPR reaction mixture into a plurality of microwells, wherein each of the plurality of microwells comprises a sample;
c. amplifying the target, if present in the sample, by isothermal amplification; and
d. detecting a signal in each of the plurality of microwells, wherein a detectable signal in a given microwell indicates the presence of the target in the microwell.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the Cas endonuclease comprises Cas12a.

### Claim 4

The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture further comprises a forward competition primer and a reverse competition primer.

### Claim 5

The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture further comprises a DNA polymerase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the DNA polymerase comprises Bst DNA polymerase.

### Claim 7

The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture further comprises a reverse transcriptase.

### Claim 8

The method any one of the preceding claims, wherein isothermal amplification comprises incubating the warm-start CRISPR reaction mixture at a temperature of about 50° C.-60° C. for at least about 10 minutes.

### Claim 9 (depends on 8)

The method of claim 8, comprising incubating for at least about 30 minutes.

### Claim 10 (depends on 8)

The method of claim 8, comprising incubating for at least about 60 minutes.

### Claim 11 (depends on 8)

The method of claim 8, comprising incubating for about 90 minutes.

### Claim 12 (depends on 8, 9, 10, 11)

The method of any one of claims 8-11, wherein isothermal amplification comprises incubating the warm-start CRISPR reaction mixture at a temperature of about 52° C.

### Claim 13

The method of any one of the preceding claims, wherein the target is viral nucleic acid.

### Claim 14 (depends on 13)

The method of claim 13, wherein the target is viral nucleic acid from an upper respiratory pathogen selected from SARS-CoV-2, coronavirus, rhinovirus, influenza, respiratory syncytial virus, adenovirus, parainfluenza, human immunodeficiency virus, human papillomavirus, rotavirus, hepatitis C virus, zika virus, Ebola virus, tuberculosis, Borrelia burgdorferi, Staphylococcus, Aspergillus, and Streptococcus pyogenes.

### Claim 15 (depends on 14)

The method of claim 14, wherein the target is SARS-CoV-2 nucleic acid.

### Claim 16 (depends on 15)

The method of claim 15, wherein the target is nucleic acid within the nucleoprotein (N) gene of SARS-CoV-2.

### Claim 17 (depends on 16)

The method of claim 16, wherein the target-specific crRNA comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 9.

### Claim 18 (depends on 17)

The method of claim 17, wherein the target-specific crRNA comprises a nucleotide sequence set forth in SEQ ID NO: 9.

### Claim 19

The method of any one of the preceding claims, wherein the outer primers comprise a forward outer primer and a reverse outer primer, wherein the forward outer primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 1 and wherein the reverse outer primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 2.

### Claim 20 (depends on 19)

The method of claim 19, wherein the forward outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 1 and wherein the reverse outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 2.

### Claim 21

The method of any one of the preceding claims, wherein the phosphorothioated inner primers comprise a forward inner primer and a reverse inner primer, wherein the forward inner primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 4, and wherein the reverse inner primer comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 6.

### Claim 22 (depends on 21)

The method of claim 21, wherein the forward inner primer comprises a nucleotide sequence set forth in SEQ ID NO: 4, and wherein the reverse inner primer comprises a nucleotide sequence set forth in SEQ ID NO: 6.

### Claim 23

The method of any one of the preceding claims, wherein the warm-start CRISPR reaction mixture comprises less than 0.4 U/μl pyrophosphatase.

### Claim 24 (depends on 23)

The method of claim 23, wherein the warm-start CRISPR reaction mixture comprises about 0.2 U/μl pyrophosphatase.

### Claim 25

The method of any one of the preceding claims, wherein the sample comprises a nasal sample, a nasopharyngeal sample, an oropharyngeal sample, a mid-turbinate sample, or a saliva sample.

### Claim 26

The method of any one of the preceding claims, wherein the sample is obtained from a subject suspected having a viral infection.

### Claim 27 (depends on 26)

The method of claim 26, wherein the sample is obtained from a subject suspected of having an upper respiratory infection.

### Claim 28 (depends on 27)

The method of claim 27, wherein the sample is obtained from a subject suspected of having infection with an upper respiratory pathogen selected from SARS-CoV-2, coronavirus, rhinovirus, influenza, respiratory syncytial virus, adenovirus, parainfluenza, human immunodeficiency virus, human papillomavirus, rotavirus, hepatitis C virus, zika virus, Ebola virus, tuberculosis, Borrelia burgdorferi, Staphylococcus, Aspergillus, and Streptococcus pyogenes.

### Claim 29 (depends on 28)

The method of claim 28, wherein the sample is obtained from a subject suspected of having SARS-CoV-2.

### Claim 30

A kit comprising a primer having at least 90% sequence identity to SEQ ID NO: 1, a primer having at least 90% sequence identity to SEQ ID NO: 2, a primer having at least 90% sequence identity to SEQ ID NO: 4, a primer having at least 90% sequence identity to SEQ ID NO: 6, a primer having at least 90% sequence identity to SEQ ID NO: 7, and a primer having at least 90% sequence identity to SEQ ID NO: 8.

### Claim 31 (depends on 30)

The kit of claim 30, comprising a primer having the amino acid sequence set forth in SEQ ID NO: 1, a primer having the amino acid sequence set forth in SEQ ID NO: 2, a primer having the amino acid sequence set forth in SEQ ID NO: 4, a primer having the amino acid sequence set forth in SEQ ID NO: 6, a primer having the amino acid sequence set forth in SEQ ID NO: 7, and a primer having the amino acid sequence set forth in SEQ ID NO: 8.

### Claim 32 (depends on 30, 31)

The kit of claim 30 or claim 31, further comprising a target-specific crRNA comprising a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 9.

### Claim 33 (depends on 32)

The kit of claim 32, further comprising a target specific crRNA comprising the nucleotide sequence set forth in SEQ ID NO: 9.

### Claim 34 (depends on 30, 31, 32, 33, 34)

The kit of any one of claims 30-34, further comprising pyrophosphatase.
